Why Choose Noble Life Sciences for Orthotopic Models?
Clinically Relevant Tumor Microenvironment
Tumors develop in their native organ, ensuring realistic disease progression
Validated for Immuno-Oncology & Metastatic Studies
Ideal for checkpoint inhibitors, CAR-T therapies, and other therapies with translational relevance.
Advanced In Vivo Imaging & Tumor Monitoring
Real-time bioluminescence, near-infrared (NIR) imaging , and micro-CT
Customizable & Patient-Derived Tumor Options
Choose from cell-line xenografts, PDX, and genetically engineered models
GLP-Compliant, AAALAC-Accredited Facility
Providing high-quality, reproducible, and regulatory-ready preclinical data
Noble’s orthotopic models allow researchers to assess drug responses in a highly predictive environment, reducing late-stage clinical failures.
Orthotopic Tumor Model Portfolio
Solid Tumor Orthotopic Models
| Cancer Type | Tumor Lines | Key Study Endpoints |
| Brain Cancer |
U87MG, GL261 | Tumor burden, survival analysis, radiation and chemotherapy response |
| Breast Cancer |
MDA-MB-231, 4T1-luc, MCF-7 BT474 |
Tumor growth, metastasis tracking, ADC response and targeting therapy |
| Colorectal Cancer | HCT-116, HT-29, MC38, CT26 | Immune infiltration, checkpoint inhibitor response |
| Lung Cancer (NSCLC & SCLC) | A549, H292, LL-luc | Tumor metastasis, immunotherapy response |
| Prostate Cancer | PC-3, LNCAP, DU145 | Tumor burden, angiogenesis, metastasis studies |
| Pancreatic Cancer | Panc02, MiaPaCa-2 | Drug penetration, metastatic spread |
| Renal Cancer | 786-O, Renca | Response to tyrosine kinase inhibitors (TKIs) |
| Ovarian Cancer | OVCAR-3, A2780, SKOV-3 | Platinum-based chemotherapy response |
Hematological & Metastatic Orthotopic Models
- Leukemia & Lymphoma Models – MV4-11, THP-1, Ramos (studying immune interactions and blood-based biomarkers)
- Metastatic Models – Tracking metastasis to lung, liver, bone, and brain in real-time using bioluminescence imaging
Advanced Imaging & Translational Research Capabilities
Non-Invasive In Vivo Tumor Imaging
- Bioluminescence Imaging (BLI) – Real-time tracking of tumor growth and metastasis
- Near-Infrared (NIR) Imaging – Label tumors or immune cells for deep-tissue imaging and immune trafficking studies in vivo.
- Micro-CT & MRI – Tumor localization, vascularization, and drug penetration analysis
These imaging technologies allow for longitudinal tracking of disease progression and treatment response.
Immuno-Oncology & Tumor Microenvironment Analysis
- Multiplex Flow Cytometry – T-cell activation, tumor-infiltrating lymphocyte (TIL) analysis, peripheral immune populations, and lymphoid organs
- Multiplex Immunohistochemistry (IHC) – Immune cells, cytokine profiling and biomarker expression
- RNA & DNA Sequencing – Understanding tumor evolution, pathway activation, and therapy resistance
Our immune-oncology assays provide critical insights into immune cell interactions and therapy responses.
Immuno-Pharmacokinetic (PK) & Pharmacodynamic (PD) Studies
- Tumor Penetration Studies – Assessing drug distribution within tumors, and evaluation tissue-specific exposure, accumulation and clearance profiles
- Gene & Protein Expression Analysis – Defining therapeutic mechanisms of action
Supporting in-depth preclinical characterization of novel therapeutics.
How to Choose the Right Orthotopic Model?
- Early-Stage Drug Screening – CDX Models offer high reproducibility and rapid screening
- Biomarker-Driven Therapy Development – PDX Models provide patient-relevant responses
- Immune-Oncology Applications – Syngeneic & Humanized Models for checkpoint inhibitors & cell therapy
- Metastatic & Resistance Studies – Orthotopic Models for tumor microenvironment research
Selecting the right model ensures clinically relevant and translatable preclinical data.
Explore additional preclinical tumor models to support your oncology research.
